BACKGROUND: Cytokines and growth factors have been implicated in the initiation and propagation of vascular disease. Observational studies have shown associations of their circulating levels with stroke. Our objective was to explore whether genetically determined circulating levels of cytokines and growth factors are associated with stroke and its etiologic subtypes by conducting a 2-sample Mendelian randomization (MR) study.
S
troke is the leading cause of long-term disability and the second most common cause of death worldwide, 1,2 with a growing burden on global health. 3 Inflammatory mechanisms have been implicated in stroke and etiologic stroke subtypes, [4] [5] [6] and specifically demonstrated for large-artery atherosclerotic stroke. 4, 5 Cytokines and growth factors regulate the inflammatory response 4 and thus may serve as targets for cardiovascular disease prevention. 7 Indeed, the CAN-TOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) recently demonstrated the potential of targeting specific inflammatory cytokines in reducing vascular end points. 8 Few studies have investigated associations between the circulating levels of inflammatory cytokines and risk of stroke. Levels of interleukin (IL)-1β and IL-6 were found to be associated with incident and recurrent ischemic stroke. 4 However, these associations derived from observational studies preclude conclusions about causal relationships because of possible confounding and reverse causation. 9 Also, associations with etiologic stroke subtypes were not investigated in depth. 4 Hence, the potential causative role of individual cytokines in determining stroke risk remains elusive. Developing meaningful strategies for stroke prevention will require defining these relationships. 10 Mendelian randomization (MR) aims to overcome the limitations of conventional epidemiological studies with respect to confounding and reverse causation. By using genetic variants as instrumental variables for a trait, MR enables an investigation of associations independent of the conventional biases accompanying observational studies. 11 A recent genome-wide association study (GWAS) in 8293 healthy subjects of Finnish ancestry identified multiple common genetic variants that influence circulating levels of 41 cytokines and growth factors (referred to hereafter as cytokines for simplicity), 12 thus providing comprehensive data on genetic determinants of circulating inflammatory biomarkers. 12 Here, by leveraging data from this recent GWAS on cytokines 12 and the largest GWAS meta-analysis on stroke and stroke subtypes to date, 13 we implemented a 2-sample MR study to (1) explore the associations between genetic predisposition to higher or lower circulating cytokine levels with risk of any stroke; (2) evaluate specific associations with ischemic stroke and its major etiologic subtypes (large-artery stroke, cardioembolic stroke, and small-vessel stroke), and with intracerebral hemorrhage, as well; (3) validate these findings in UK Biobank as an independent cohort; (4) compare the MR associations with estimates of association derived from meta-analyses of observational studies; and (5) examine the association with etiologically related cardiovascular outcomes including coronary artery disease (CAD), myocardial infarction (MI), and atrial fibrillation (AF).
METHODS

Access to Publicly Available Data
The analyses for this study were based on publicly available summary statistics from GWAS consortia. The web links for downloading the data are provided in Table I in the onlineonly Data Supplement along with descriptive characteristics of the consortia. The retrieved summary data for the current analysis and the code script are available on reasonable request to the corresponding author. Because all analyses have been based on publicly available summary statistics and not individual-level data, no ethical approval from an institutional review board was required.
Study Design and Data Sources
The overall design of this study is displayed in Figure 1 . Table  I in the online-only Data Supplement summarizes our data sources for this MR study. The genetic instruments were taken from publicly available summary statistics. 12 For each of the 41 cytokines (full list provided in Table II in the onlineonly Data Supplement) we selected single-nucleotide polymorphisms (SNPs) associated with their circulating levels at a significance threshold of a false discovery rate <5%.
14 To avoid bias by selection of false-positive instruments, we performed additional analyses using a genome-wide threshold of significance (P<5×10 -8 ). After extracting the summary statistics for significant SNPs, we pruned all SNPs in linkage disequilibrium (r 2 <0.1 in the European 1000 Genomes Project reference panel), retaining SNPs with the lowest P value as an independent instrument. We identified 698 SNPs not in linkage disequilibrium to be significantly associated with circulating cytokine levels; 615 of them were also available in the MEGASTROKE data set. To avoid the use of pleiotropic instruments, we excluded 126 SNPs that were associated with levels of >1 cytokine, 15 leaving 489 SNPs as the final instruments. These instruments related to the circulating levels of
Clinical Perspective
What Is New?
• Genetic predisposition to higher circulating levels of monocyte chemoattractant protein-1 was associated with higher risk of stroke.
• Associations were also found for etiologic stroke subtypes, specifically large-artery stroke and cardioembolic stroke.
• Genetically determined levels monocyte chemoattractant protein-1 also associated with higher risk of the related phenotypes of coronary artery disease and myocardial infarction.
What Are the Clinical Implications?
• Additional work is needed to determine whether targeting monocyte chemoattractant protein-1 or its downstream effectors is a meaningful strategy for lowering stroke risk.
ORIGINAL RESEARCH ARTICLE
23 cytokines, whereas for 18 cytokines, no SNPs associated with their circulating levels at a significance level of false discovery rate <5% could be identified.
The primary outcomes for this study were any stroke, any ischemic stroke, etiologic ischemic stroke subtypes defined by TOAST criteria (Trial of Org 10172 in Acute Stroke Treatment) (large-artery stroke, cardioembolic stroke, and small-vessel stroke), 16 and intracerebral hemorrhage. We extracted estimates for the associations of the selected instruments with any stroke, any ischemic stroke and its subtypes from the MEGASTROKE multiancestry GWAS data set (67 162 cases; 454 450 controls). 13 Sensitivity analyses restricted to individuals of European ancestry (40 528 cases; 445 396 controls) were conducted, to minimize ancestral mismatch with the Finnish population used for the discovery GWAS on cytokines. 12 For intracerebral hemorrhage, we extracted data from publicly available summary statistics of a GWAS meta-analysis on 1545 cases and 1481 controls of European ancestry. 17 We computed F statistics to quantify the strength of the selected instruments 18 and performed power calculations. 19 The F statistic for the 489 instrument SNPs ranged from 17 to 789 (Table III in 
Statistical Analysis
After extraction of data and harmonization of the effect alleles across GWASs, we computed individual MR estimates and standard errors from the SNP-cytokine and SNP-outcome associations using the Wald estimator and the Delta method that weight all estimates based on the magnitude of the SNPcytokine association. 23 The MR association between each cytokine and stroke was estimated after pooling individual SNP MR estimates using fixed-effects inverse variance-weighted (IVW) meta-analysis. 23 Statistical significance for the MR associations with stroke was set at a P value corrected for multiple comparisons (based on the number of cytokines) using the Bonferroni method. We further report on results corrected for both the number of cytokines and the number of examined phenotypes. A P<0.05, but above the Bonferroni-corrected threshold, was considered as suggestive for association. The IVW MR approach assumes that instruments affect the outcome only through the exposure under consideration, and not by some alternative pathway. 23 Any violation of this assumption would represent horizontal pleiotropy of the instrument and could introduce bias to the MR estimate. In the absence of any such horizontal pleiotropy, there would not be any expected heterogeneity in the MR estimates obtained from different instruments. As such, heterogeneity markers (I 2 >25% or Cochran Q-derived P<0.05) from the IVW MR were used as indicators of possible horizontal pleiotropy. 24 For cytokines showing either significant or suggestive associations or significant heterogeneity in the primary IVW MR analysis, we conducted additional sensitivity analyses that vary ORIGINAL RESEARCH ARTICLE in their underlying assumptions regarding the presence of pleiotropic genetic variants that may be associated with the outcome independently of the exposure. In particular, we used MR-Egger regression, which requires that the strengths of the instruments are independent of their direct associations with the outcome, 25 and the weighted median method, which requires that at least half of the information for the MR analysis comes from valid instruments. 26 We used the intercept obtained from the MR-Egger regression as a measure of directional pleiotropy (P<0.05 was considered significant), 25 and also tested for outlier SNPs using MR-Pleiotropy Residual Sum and Outlier. 27 To generate MR estimates unaffected by the presence of pleiotropic pathways acting through cardiovascular risk factors, we performed regression-based multivariable MR with summary genetic association estimates 28 that adjusted for the genetic association of instruments with circulating lipid levels (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides), type 2 diabetes mellitus, and blood pressure measurements (systolic and diastolic blood pressure, hypertension). Genetic association estimates for these phenotypes were extracted from the GLGC (Global Lipids Genetic Consortium), 29 the DIAGRAM consortium (Diabetes Genetics Replication and Meta-Analysis), 30 and the UK Biobank, 31 published by the Neale laboratory, respectively.
Instrument SNPs for cytokines showing significant associations with stroke were mapped to the nearest gene by using the GRCh37/hg19 reference genome. We used the STRING database (Search Tool for the Retrieval of Interacting Genes) 32 to look for protein-protein interactions between gene products and the cytokines and identified interacting subnetworks. As a sensitivity analysis, and to gain further insight into the biological processes involved in the examined associations, we performed IVW MR analyses with SNPs restricted to the specific subnetworks.
The GWAS used to select cytokine instruments included no replication, and its estimates of association were further adjusted for body mass index, besides age and sex. 12 As a sensitivity analysis for bias that may be introduced by this body mass index adjustment, 33 we also calculated an unweighted allele score for any cytokines demonstrating a significant association in our main IVW MR analysis. 34 Such an unweighted allele score may offer evidence of a causal effect of the exposure on the outcome without suffering from bias in the genetic association estimates for the exposure, although this is at the cost of not being able to estimate the magnitude of any such effect. 34 Statistical analyses were conducted in Stata 13.1 (StataCorp).
Meta-Analysis of Observational Studies
For the cytokines that showed significant associations with stroke in MR, we performed a meta-analysis of observational studies. We searched Medline until December 10, 2017 (search strategy is available in the Methods in the onlineonly Data Supplement), for case-control studies comparing the circulating cytokine levels between patients with stroke and controls, and cohort studies exploring the association of baseline levels with incident or recurrent stroke. We extracted relevant data and applied random-effects meta-analyses for hazard ratios (cohort studies) or standardized mean differences (case-control studies). We evaluated heterogeneity with the I 2 and the Cochran Q.
RESULTS
Genetically Determined Circulating Levels of Cytokines and Risk of Stroke
The primary results of the MR analyses for the 23 cytokines are presented in Figure 2 . Following Bonferroni correction for testing multiple cytokines (P<0.05/23=2.2×10 -3 ), the only cytokine showing sta- Figure 2 . Mendelian randomization associations of circulating cytokine and growth factor levels with stroke and stroke subtypes. Shown are the results derived from the fixed-effects inverse variance weighted meta-analysis. BNGF indicates beta nerve growth factor; CTACK, cutaneous T-cellattracting chemokine; GRO-α, growth-regulated oncogene alpha; HGF, hepatocyte growth factor; IL, interleukin; IP-10, interferon gamma-induced protein 10 MCP-1, monocyte chemoattractant protein-1; MIF, macrophage migration inhibitory factor; MIG, monokine induced by gamma interferon; MIP-1b, macrophage inflammatory protein 1 beta; PDGF-bb, platelet-derived growth factor-bb; SCF, stem cell factor; SCGF-b, stem cell growth factor beta; SNP, single-nucleotide polymorphism; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; and VEGF, vascular endothelial growth factor. *Significant heterogeneity (I 2 >25% or Cochran Q-derived P<0.05). †Bonferroni-corrected threshold for number of tested cytokines. ‡Bonferroni-corrected threshold for number of cytokines and number of phenotypes.
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tistically significant associations with stroke was the CC chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2). As depicted in Figure 3A and Figure I in the online-only Data Supplement, genetically determined higher circulating MCP-1 levels (1 SD increase) were associated with 6% higher odds for both any stroke (OR, Figure 3B ), although with wider confidence intervals as would be expected given the lower statistical power of these approaches. 25, 26 Use of an unweighted allele score for the MCP-1 instrument SNPs also showed statistically significant associations with risk of large-artery (P=1.5×10 -4 ) and cardioembolic stroke (P=2.8×10 -4 ). The significant association between MCP-1 and outcomes was retained both when restricting the analysis to individuals of European ancestry ( Figure II To explore whether the MR association between genetically determined MCP-1 levels and stroke was attributable through pleiotropic pathways relating to cardiovascular risk factors, we conducted multivariable MR analysis adjusting for circulating lipid levels, type 2 diabetes mellitus, and blood pressure. The results remained stable regardless of the model (unadjusted, single, or fully adjusted model), thus supporting an independent association between MCP-1 levels and stroke and stroke subtypes (Table) .
None of the genetic instruments for MCP-1 was within or close to the MCP1 gene. Assessing genes closest to the instruments for MCP-1, we noted that several of them encoded proteins that show a biological relationship with MCP-1, eg, CCR2, the main receptor for MCP-1 (Table IV in the online-only Data Supplement). To minimize the risk of using nonspecific instruments that might exert pleiotropic effects, we performed an additional sensitivity analysis focusing on instruments in the vicinity of these genes. Using the STRING database, we found the chemokine receptors CCR2, CCR1, CCR3, and CCR9, the chemokine-binding protein CCBP2, and the receptor of the complement C5a (C5aR1) to integrate into a subnetwork of established interactions with MCP-1 ( Figure IVA in Several other cytokines not reaching the Bonferronicorrected threshold showed suggestive (P<0.05) associations with risk of stroke in MR analyses: genetic predisposition to higher levels of eotaxin, interferon gamma-induced protein 10, monokine induced by gamma interferon, platelet-derived growth factor-bb, and vas- The results are presented as odds ratios (95% CIs) for the effect of 1 SD increase in MCP-1 levels. DBP indicates diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; MCP-1, monocyte chemoattractant protein-1; SBP, systolic blood pressure; T2D, type 2 diabetes mellitus; and TG, triglyceride.
*Restricted to LDL-C to avoid collinearity with HDL-C and TG levels. †Restricted to SBP to avoid collinearity with DBP and HTN.
cular endothelial growth factor were associated with an higher risk of stroke, whereas predisposition to higher levels of stem cell factor and stem cell growth factor beta were associated with lower risk of stroke ( Figure 2 ).
Genetically Determined Circulating Levels of MCP-1 and Risk of Stroke in UK Biobank
We next explored the MR association between genetically determined MCP-1 levels and risk of any stroke and risk of any ischemic stroke in the independent UK Biobank sample and meta-analyzed the MEGASTROKE and UK Biobank data ( Figure 4A and Figure V A, MR-derived associations between genetically determined circulating MCP-1 levels (1 SD increase) and risk of any stroke and any ischemic stroke in MEGAS-TROKE, in UK Biobank, and a meta-analysis of both samples. B, Meta-analysis-derived associations between circulating MCP-1 levels (1 SD increase) and risk of ischemic stroke in case-control and cohort studies. k refers to number of included studies. I 2 in Figure 4A refers to heterogeneity in the MR analysis (inverse variance weighted method), and, in Figure 4B , to heterogeneity in the random-effects meta-analyses of observational studies. HR indicates hazard ratio; MCP-1, monocyte chemoattractant protein-1; MR, Mendelian randomization; OR, odds ratio; and SMD, standardized mean difference.
ORIGINAL RESEARCH ARTICLE 1.06; 95% CI, 1.03-1.09; P=2×10 -4 ) and any ischemic stroke (OR, 1.06; 95% CI, 1.03-1.10; P=7×10 -4 ) in the meta-analysis of MEGASTROKE and UK Biobank.
Circulating Levels of MCP-1 and Risk of Stroke: Meta-Analysis of Observational Studies
Next, we compared the MR estimates with those derived from a meta-analysis of observational studies. Our search yielded 17 case-control studies of patients with ischemic stroke and controls, 2 cohort studies on patients with a history of stroke or cardiovascular disease exploring the risk of recurrent ischemic stroke, and 1 case-cohort study of incident ischemic stroke in a community population (Tables V and VI Figure 5 depicts the MR association between genetically determined MCP-1 levels and risk of CAD, MI, and AF.
Genetically Determined Circulating Levels of MCP-1 and Etiologically Related Vascular Outcomes
Genetic predisposition to higher MCP-1 levels was associated with CAD (OR per 1 SD increase, 1.04; 95% CI, 1.00-1.08; P=0.04; 184 305 individuals, 60 801 cases) and MI (OR, 1.05; 95% CI, 1.01-1.09; P=0.02; 167 180 individuals, 43 676 cases). Given the association of MCP-1 with cardioembolic stroke, we further explored the relationship between genetically determined MCP-1 levels and risk of AF in MR analysis, but found no association (OR, 0.96; 95% CI, 0.91-1.01; P=0.09).
DISCUSSION
Exploring 41 cytokines in a 2-sample MR approach involving the largest GWAS data sets available, we found that genetic predisposition to higher levels of MCP-1/ CCL2 is associated with higher risk of any stroke, any ischemic stroke, large-artery stroke, and cardioembolic stroke. The results were stable in alternative MR methods and sensitivity analyses and remained significant after adjustment for cardiovascular risk factors. Moreover, effect sizes for any stroke and any ischemic stroke were similar in the UK Biobank. We further found associations between genetic predisposition to higher MCP-1 levels and higher risk of CAD and MI as etiologically related outcomes. Collectively, our findings suggest that lifelong elevated circulating MCP-1 levels increase the risk of stroke.
The directionality of the MR association between genetically determined levels of MCP-1 and risk of largeartery stroke is consistent with experimental data showing a key role for this chemokine in atherogenesis and atheroprogression. Acting mainly through its receptor CCR2, MCP-1 is the prototypical CC family chemokine that is upregulated by chronic inflammatory conditions and attracts monocytes to the subendothelial space of the atherogenic arterial wall. 36 Mice lacking MCP-1 37 or CCR2 38 are less susceptible to atherosclerosis, and anti-MCP-1 gene therapy, 39 MCP-1 competitors, 40 and CCR2 
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antagonists 41 reduce plaque size and inhibit plaque progression and destabilization in experimental atherosclerosis. Conversely, overexpression of MCP-1 leads to inflammation, accumulation of lipids, and smooth muscle cell proliferation in atherosclerotic plaques. 42 We further found an MR association between genetic predisposition to higher MCP-1 levels and risk of cardioembolic stroke. Genetic predisposition to higher MCP-1 levels is associated with higher risk of CAD and MI, which could promote the formation of left ventricular thrombus from myocardial damage, thus resulting in cardioembolic stroke. Furthermore, MCP-1 has been reported to promote myocardial fibrosis, 43 an established risk factor for AF. 44 However, we found no association between the genetic instruments for MCP-1 and AF risk. Other investigators have found an association between circulating MCP-1 levels and the presence of atrial thrombi in patients with AF. 45 Hence, it might be that MCP-1 increases the risk of cardioembolic stroke by promoting thrombus formation in patients with established AF. Alternative explanations for the association between circulating MCP-1 levels and cardioembolic stroke might include less frequent causes of cardioembolism, such as valvular disease and the misclassification of patients with multiple competing stroke etiologies including atherosclerosis.
In contrast, our analysis provides no evidence for an association of genetically determined MCP-1 levels with small-vessel stroke even though the sample size was larger than for other stroke subtypes. In fact, we found none of the cytokines to be associated with small-vessel stroke (all P>0.05, Figure 2 ). Overall, these observations agree with the notion that inflammatory processes are less important in small-vessel disease than in large-artery atherosclerosis, although this has so far not been systematically examined.
The lack of a signal with intracerebral hemorrhage, and, in particular, deep intracerebral hemorrhage, which, like small-vessel stroke, is attributed to smallvessel disease, 17 is in line with this result. However, this analysis was based on a rather small sample size. Also, following restriction of the analysis to SNPs in the vicinity of genes interacting with MCP-1, we identified a significant association between genetically determined MCP-1 levels and intracerebral hemorrhage. This difference in results might relate to the exclusion of nonspecific instruments in the sensitivity analyses and should be explored further in larger samples.
Our meta-analysis of case-control studies revealed higher circulating MCP-1 levels in patients with ischemic stroke than in healthy controls. Our systematic search identified only 3 prospective cohort studies, one on incident 46 and 2 on recurrent stroke events, 47, 48 none of which showed significant results. However, these studies had small sample sizes and a low number of events. Also, ischemic stroke subtypes were not considered, thus precluding meaningful comparisons with our MR results. It is interesting to note that observational cohort studies on CAD found higher MCP-1 levels to be associated with a higher risk of incident 49 and recurrent 50 events, consistent with the observed association with atherosclerotic stroke. Serial measurements of MCP-1 in large population-based cohorts with data on ischemic stroke subtypes would offer further insights into the relationship between MCP-1 and the risk of stroke.
Targeting specific inflammatory cytokines might reduce vascular risk. The recent multicenter CANTOS trial showed that canakinumab, a monoclonal antibody against IL-1β, decreases the rate of recurrent cardiovascular events, including nonfatal MI, nonfatal stroke, and cardiovascular mortality, among patients with MI and elevated circulating C-reactive protein levels. 8 Unfortunately, the original cytokine GWAS did not identify any genetic instruments for IL-1β circulating levels, 12 thus precluding a comparison of the MR results with the results of the CANTOS trial. 8 The MCP-1/ CCR2 pathway was targeted in a small phase II clinical trial in patients with risk factors for atherosclerosis and elevated circulating C-reactive protein levels. MLN1202, a humanized monoclonal antibody against CCR2, reduced C-reactive protein levels after 4 and 12 weeks. 51 However, the effects on clinical end points were not assessed 51 and would need to be determined in a larger trial.
This study has several methodological strengths. We used the most recent and comprehensive data set for cytokine levels and the largest available GWAS data set for stroke and stroke subtypes. Results were confirmed through sensitivity analyses for pleiotropy, including alternative MR methods, in subanalyses on a biologically plausible protein-protein interaction network, and in analyses on etiologically related outcomes (CAD and MI).
Our study also has limitations. First, none of the SNPs used as instruments for MCP-1 were located in the vicinity of the MCP1 gene, thus precluding analyses restricted to SNPs within this locus. Consequently, although we found no statistical evidence for pleiotropy, we cannot preclude nonspecific effects of the MCP-1 trans-acting instruments. Second, our instrument selection was based on a single-discovery GWAS that adjusted for body mass index. Although the association remained consistent when using an unweighted allele score, we cannot exclude that the body mass index adjustment led to collider bias during instrument selection. Third, we could not obtain reliable genetic instruments for 18 cytokines, and several analyses for ischemic stroke subtypes were underpowered. Thus, we might have missed associations for several cytokines that have previously been implicated in vascular disease such as IL-1β, tumor necrosis factor-α, and IL- 265 ORIGINAL RESEARCH ARTICLE 6. Targeted studies incorporating further GWAS data on individual cytokines might reveal additional associations not captured by our approach. Fourth, genetic instruments were selected using a false discovery rate-based approach, which might have weakened the instruments. However, the F statistics were high, and the results were in line with those derived when selecting instruments based on the genome-wide threshold (P<5×10 -8 ). Finally, the UK Biobank analysis was rather underpowered and did not include stroke subtypes. Yet the consistency of both the direction and magnitude of the associations between genetically determined MCP-1 and risk of any stroke and any ischemic stroke supports our results.
In conclusion, this study demonstrates that lifelong elevated circulating MCP-1 levels are associated with higher risk of stroke and, in particular, with the largeartery and the cardioembolic subtypes. Future studies should explore in more depth whether targeting MCP-1 or its downstream effectors could be a meaningful strategy to reduce stroke risk. the following consortia for making data publicly available: CARDIoGRAMplusC4D Consortium, AFGen Consortium, GLGC Consortium, and DIAGRAM Consortium. 
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